About Glafabra Therapeutics, Inc.
Glafabra Therapeutics is a biotechnology company developing cell-based gene therapy for lysosomal storage disorders, including Fabry, Gaucher, and Pompe diseases. The company has completed a pilot clinical trial in Canada and plans to initiate U.S. trials in late 2027.
Development of cell-based gene therapy for lysosomal storage disordersClinical trial execution (completed pilot in Canada)FDA Orphan Drug Designation for GT-GLA-S03
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to Glafabra Therapeutics, Inc. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.